肺癌是全球发病率和死亡率最高的恶性肿瘤之一。肺癌最常见的组织学类型之一是肺腺癌（LUAD）。尽管医学的发展已经显着改善了一些患者的预后，但总生存率（OS）仍然很低。在葡萄糖缺乏的SLC7A11过表达的癌细胞中，二硫键的积累导致肌动蛋白细胞骨架蛋白之间的二硫键异常，干扰其组织，最终导致肌动蛋白网络崩溃和细胞死亡。这种细胞死亡模式称为二硫键死亡。研究表明，二硫键下垂可能成为癌症治疗的新靶点。然而，二硫键在 LUAD 中的作用仍不清楚。LUAD 转录组和临床信息来自癌症基因组图谱 (TCGA)。进行共表达分析、最小绝对收缩和选择算子（LASSO）回归和Cox回归分析来筛选二硫下垂相关lncRNA（DRL）并建立预后模型。 Kaplan-Meier 曲线、Cox 回归分析和受试者工作特征 (ROC) 曲线用于验证模型。然后制作列线图来预测 LUAD 患者的预后。最后，利用新鲜采集的临床样本来验证DRLs在LUAD中的表达。建立了包含6个DRLs的预后模型来预测LUAD的预后，与其他临床变量相比具有优越的预后价值。 Cox回归分析显示，T分期、N分期和风险评分被确定为影响LUAD预后的自变量。 ROC曲线显示该模型具有中等诊断价值，1年AUC为0.684，3年为0.664，5年为0.588。此外，通过药物敏感性分析获得了九种与 LUAD 治疗相关的药物。 LUAD组织验证显示AC012073.1、AC012615.1、EMSLR和SNHG12高表达，而AL606834.1和AL365181.2低表达。筛选并验证了6个DRL，构建了预后模型，可以准确预测预后LUAD 预后。它为进一步探索 LUAD 的分子机制以及识别诊断、预后和治疗目标的潜在生物标志物奠定了基础。© 2024 作者。

Lung cancer is one of the malignant tumors with the highest rates of morbidity and mortality worldwide. One of the most common histological types of lung cancer is lung adenocarcinoma (LUAD). Despite the fact that development in medicine has significantly improved some patients' prognoses, the overall survival (OS) rate is still very low. In glucose-deficient SLC7A11-overexpressed cancer cells, the accumulation of disulfide molecules leads to abnormal disulfide bonding between actin cytoskeletal proteins, interferes with their tissues, and eventually leads to actin network collapse and cell death. This mode of cell death is called disulfidptosis. Studies have shown that disulfidptosis may be a new target for cancer treatment. However, the role of disulfidptosis in LUAD is still unknown.LUAD transcriptome and clinical information from The Cancer Genome Atlas (TCGA) was downloaded. The co-expression analysis, Least Absolute Shrinkage and Selection Operator (LASSO) regression, and Cox regression analysis was performed to screen the disulfidptosis-related lncRNAs (DRLs) and build the prognostic model. Kaplan-Meier curve, Cox regression analysis, and receiver operating characteristic (ROC) curve was used to validate the model. Then a nomogram is made to predict the prognosis of LUAD patients. Finally, fresh-collected clinical samples were used to verify the expression of DRLs in LUAD.The prognostic model with six DRLs was developed to predict the prognosis of LUAD, with superior prognosis value compared to other clinical variables. The Cox regression analysis revealed that T stage, N stage and the risk score were identified as independent variables that affected LUAD prognosis. ROC curve revealed that the model has a moderate diagnostic value, with an AUC of 1-year 0.684, 3-year 0.664, and 5-year 0.588. Moreover, nine medications connected to LUAD treatment were acquired through drug sensitivity analysis. LUAD tissue validation showed that AC012073.1, AC012615.1, EMSLR, and SNHG12 were highly expressed, while AL606834.1 and AL365181.2 with low expression.Six DRLs were screened and verified to construct the prognostic model, which can accurately predict the LUAD prognosis. It establishes a basis for further exploration into the molecular mechanisms underlying LUAD and identification of potential biomarkers for diagnosis, prognosis, and therapeutic targets.© 2024 The Authors.